Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Relieves pain associated with post-herpetic neuralgia (PHN). NDA 215029, held by Medrx USA. Lidocaine.
As of Nov 14, 2026, NDA 215029 (Bondlido), held by Medrx USA, was first approved by FDA on Sep 24, 2025, with 0 approved supplements and 1 published complete response letter.
First approved: Sep 24, 2025
Review: Standard
Supplements approved: 0
Complete response letters: 1
What It's For
From the FDA-approved label (Indications and Usage)
BONDLIDO (lidocaine topical system 10%) is indicated in adults for relief of pain associated with post-herpetic neuralgia (PHN).
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters.Drugs@FDA and FDA complete response letters
